*Dr. Sandra Banack analyzing exosome test data.*

At Brain Chemistry Labs, contrary to many other labs, we support the idea that misfolded β-amyloid and tau proteins are consequences rather than causes of Alzheimer’s disease.

As a result, we fear using β-amyloid and tau as blood-borne markers to diagnose and treat Alzheimer’s disease is too late in the disease process to modify the outcome.

We recently published our discovery of a unique metabolite that can diagnose Alzheimer’s at far earlier stages. Our test may even be predictive in pre-symptomatic cases.

As a way of increasing the sensitivity of the test, we will expand the number of blood samples in our cohort by incorporating blood samples from our upcoming clinical trial for Mild Cognitive Impairment, scheduled to commence in August, 2022.